Skip to content
Ilorasertib
Ilorasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target aurora kinase C, aurora kinase A, aurora kinase B, vascular endothelial growth factor receptor 3, vascular endothelial growth factor receptor 2, macrophage colony-stimulating factor 1 receptor, platelet-derived growth factor receptor alpha, receptor-type tyrosine-protein kinase FLT3, platelet-derived growth factor receptor beta, mast/stem cell growth factor receptor Kit, and vascular endothelial growth factor receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8021———3
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameILORASERTIB
INNilorasertib
Description
Ilorasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target aurora kinase C, aurora kinase A, aurora kinase B, vascular endothelial growth factor receptor 3, vascular endothelial growth factor receptor 2, macrophage colony-stimulating factor 1 receptor, platelet-derived growth factor receptor alpha, receptor-type tyrosine-protein kinase FLT3, platelet-derived growth factor receptor beta, mast/stem cell growth factor receptor Kit, and vascular endothelial growth factor receptor 1.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Identifiers
PDB—
CAS-ID1227939-82-3
RxCUI—
ChEMBL IDCHEMBL1980297
ChEBI ID—
PubChem CID46207586
DrugBank—
UNII ID6L5D03D975 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AURKC
AURKC
AURKA
AURKA
AURKB
AURKB
FLT4
FLT4
KDR
KDR
CSF1R
CSF1R
PDGFRA
PDGFRA
FLT3
FLT3
PDGFRB
PDGFRB
KIT
KIT
FLT1
FLT1
Organism
Homo sapiens
Gene name
AURKC
Gene synonyms
AIE2, AIK3, AIRK3, ARK3, STK13
NCBI Gene ID
6795
Protein name
aurora kinase C
Protein synonyms
ARK-3, Aurora 3, Aurora-related kinase 3, Aurora/IPL1-related kinase 3, Aurora/IPL1/Eg2 protein 2, epididymis secretory protein Li 90, serine/threonine kinase 13 (aurora/IPL1-like), Serine/threonine-protein kinase 13, Serine/threonine-protein kinase aurora-C
Uniprot ID
Q9UQB9
Mouse ortholog
Aurkc (20871)
aurora kinase C (Q9JLC2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 30 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details